BioSpace News Archive

The company announced the closing of the previously announced underwritten public offering of 5,525,000 shares of its common stock.

In both studies, the tezacaftor/ivacaftor combination demonstrated statistically significant and clinically meaningful improvements in lung function and other measures of disease.

The company further reported signed agreements for 295 instruments year to date.

As part of this agreement, BASF will use its scientific expertise and state-of-the-art manufacturing capabilities to provide a first-to-the-market medical food product to patients with NAFLD.

In summary, the appeals process is now exhausted.

[03-November-2017] TOKYO, Nov. 3, 2017 /PRNewswire/ -- Fish have the extraordinary ability to regenerate lost fins and other appendages containing cartilage and bone. The cells responsible for the regeneration offer new clues on how to regenerate tissues in humans. Researchers at Tokyo Institute of Technology (Tokyo Tech) have found a dormant progenitor cell population in zebrafish that r

Hill-Rom expects reported revenue growth (on a constant currency basis) to be in the 3 to 4 percent range on a compound annual basis from 2017 through 2020.

Revenues for the quarter ended September 30, 2017 were $8.5 million, compared to $7.7 million for the quarter ended September 30, 2016.

Management will conduct a conference call and live webcast at 8:00 a.m. EST that day to discuss the financial results and to provide a business update.